Compare DKL & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKL | WVE |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2012 | 2015 |
| Metric | DKL | WVE |
|---|---|---|
| Price | $52.49 | $6.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $51.33 | $31.19 |
| AVG Volume (30 Days) | 57.1K | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $2.04 | $0.34 |
| Revenue Next Year | $7.16 | $83.30 |
| P/E Ratio | $17.62 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $34.59 | $5.02 |
| 52 Week High | $55.89 | $21.73 |
| Indicator | DKL | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 21.83 |
| Support Level | $50.17 | N/A |
| Resistance Level | $55.40 | $8.15 |
| Average True Range (ATR) | 1.57 | 0.78 |
| MACD | -0.10 | -0.65 |
| Stochastic Oscillator | 35.75 | 14.23 |
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.